Isotype-specific Ras·GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status

Cancer Research

Volumn 61, Issue 11, 2001, Pages 4425-4431

  Feldkamp, Matthias M ^a,b,c,d   Lau, Nelson ^a,b,d   Roncari, Luba ^a,b,d   Guha, Abhijit ^a,b,c,d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE TRIPHOSPHATE; LONAFARNIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTROCYTOMA; CONTROLLED STUDY; DRUG EFFICACY; GENE MUTATION; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOGRAFT;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ASTROCYTOMA; BRAIN NEOPLASMS; CELL DIVISION; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; GENES, RAS; GLIOBLASTOMA; GUANOSINE TRIPHOSPHATE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; MONOMERIC GTP-BINDING PROTEINS; MUTATION; PIPERIDINES; PYRIDINES; RAS PROTEINS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035360259     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. ras oncogenes in human cancers: A review
2. Regulation of p21ras by GTPase activating proteins and guanine nucleotide exchange proteins
3. The neurofibromatosis type 1 gene encodes a protein related to GAP
4. Ras genes
5. Requirement for c-ras proteins during viral oncogene transformation
6. Expression of growth factor receptors in human brain tumours
7. Expression of epidermal growth factor receptors in human brain tumors
8. Expression of an altered epidermal growth factor receptor by human glioblastoma cells
9. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas
10. Structural alterations of the epidermal growth factor receptor gene in human gliomas
11. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors
12. Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-α and their receptors in human malignant glioma cell lines
13. Expression of PDGF and PDGF receptors in human astrocytoma operative specimens supports the existence of an autocrine loop
14. Proliferation of human malignant astrocytomas is dependent on ras activation
15. Expression of activated epidermal growth factor receptors, ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens
16. Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by ras
17. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic
18. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane
19. Protein prenylation: A mediator of protein-protein interactions
20. Inhibition of human xenograft growth by treatment with the farnesyl transferase inhibitor B956
21. A peptidomimetic inhibitor of farnesyl: Protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines
22. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of antiproliferative, pro-apoptotic, and anti-angiogenic effects
23. A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
24. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice
25. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-Ras transgenic mice
26. Identification of pharmacokinetically stable 3, 10-dibromo-8-chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activities
27. Microculture tetrazolium assays: A comparison between two new tetrazolium salts. XTT and MTS
28. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
29. Determination of absolute amounts of ras GDP and GTP bound to ras in mammalian cells: Comparison of parental and ras-overproducing NIH 3T3 fibroblasts
30. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors
31. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
32. Ras C-terminal processing enzymes-new drug targets?
33. Inhibition of purified p21ras farnesyl: Protein transferase by Cys-AAX tetrapeptides
34. Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells
35. Benzodiazepine peptidomimetics: Potent inhibitors of ras farnesylation in animal cells
36. Sequence dependence of protein isoprenylation
37. Prenyl group identification of rap2 proteins: A ras superfamily member other than ras that is farnesylated
38. Evidence that farnesyltransferase inhibitors suppress ras transformation by interfering with Rho activity
39. Farnesyl transferase inhibitors induce apoptosis of ras-transformed cells denied substratum attachment
40. Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription
41. Cell growth inhibition by farnesyl-transferase inhibitors is mediated by gain of geranylgeranylated RhoB
42. High affinity for FTase and alternative prenylation contribute individually to K-Ras resistance to FTIs
43. Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I
44. Inhibition of ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II-preclinical studies in a nude mouse model
45. (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6] cyclohepta[1,2-b]-pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1- piperidinecarboxamide (SCH-66336): A very potent farnesyl protein transferase inhibitor as a novel antitumor agent
46. A Phase I and pharmacologic study of the farnesyl protein transferase (FPT) inhibitor SCH 66336 in patients with locally advanced or metastatic cancer
47. A clinical, pharmacodynamic, and pharmacokinetic Phase 1 study of SCH 66336 (SCH), an oral inhibitor of the enzyme farnesyl transferase given once daily in patients with solid tumors
48. Phase 1 and pharmacokinetic study of SCH66336, a novel FPT1, using a 2-week on, 2-week off schedule